chronic
obstruct
pulmonari
diseas
copd
current
rank
lead
caus
death
worldwid
world
health
organ
incid
increas
main
risk
factor
copd
exposur
tobacco
smoke
trigger
cascad
inflammatori
pathway
lead
diseas
induct
suscept
peopl
major
hallmark
diseas
patholog
develop
emphysema
chronic
bronchiti
lead
progress
irrevers
airflow
limit
result
continu
declin
lung
function
copd
sever
associ
acut
period
diseas
worsen
socal
exacerb
key
factor
copd
morbid
mortal
caus
acut
respiratori
distress
impact
qualiti
patient
health
respons
hospit
stay
relat
diseas
exacerb
primarili
caus
respiratori
viral
bacteri
infect
amongst
viralinduc
exacerb
account
approxim
half
case
associ
sever
acut
episod
prolong
recoveri
time
common
viral
pathogen
exacerb
patient
rhinoviru
follow
influenza
viru
rsv
coronaviru
due
target
vaccin
high
risk
group
influenza
infect
occur
less
frequent
copd
patient
western
countri
howev
continu
predomin
caus
viral
exacerb
hong
kong
singapor
copd
exacerb
link
excess
inflammatori
respons
includ
enhanc
recruit
inflammatori
cell
upregul
varieti
proinflammatori
mediat
nevertheless
underli
mechan
effect
therapeut
strategi
still
poorli
understood
firstlin
therapi
still
predominantli
reli
corticosteroid
bronchodil
limit
efficaci
thu
studi
cellular
molecular
mechan
lead
exacerb
key
identif
urgent
requir
therapeut
target
one
proinflammatori
cytokin
associ
copd
major
player
initi
persist
inflamm
anim
model
mimick
featur
copd
shown
key
induct
emphysema
inflamm
furthermor
express
significantli
enhanc
copd
patient
acut
episod
exacerb
unravel
role
viral
exacerb
might
therefor
result
overal
better
understand
mechan
exacerb
also
indic
whether
qualifi
valid
therapeut
target
promis
candid
therapeut
inhibit
signal
one
inhibitor
receptor
antagonist
anakinra
kineret
amgen
use
effect
treatment
rheumatoid
arthriti
order
investig
role
copd
exacerb
util
model
lp
elastas
induc
chronic
lung
inflamm
follow
infect
influenza
wild
type
defici
mice
found
key
driver
pulmonari
inflamm
primarili
concern
recruit
neutrophil
lung
dysfunct
driven
neutrophilia
mediat
initi
phase
viral
infect
becam
independ
peak
phase
viral
replic
treatment
anakinra
prove
effici
reduc
neutrophil
inflamm
peak
viral
replic
block
abrog
neutrophilia
earli
phase
viral
infect
taken
togeth
data
indic
blockad
could
valid
therapeut
approach
treatment
virusinduc
copd
exacerb
anim
experi
perform
accord
institut
guidelin
swiss
feder
canton
law
anim
protect
anim
experi
approv
follow
ethic
committe
servic
de
la
consomm
et
de
affair
affair
canton
de
vaud
switzerland
permit
number
balbc
mice
week
age
purchas
charl
river
laboratori
defici
mice
background
receiv
prof
iwakura
tokyo
univers
scienc
japan
bred
hous
mice
expos
intranas
mixtur
lp
e
coli
sigmaaldrich
u
porcin
pancreat
elastas
epc
total
volum
treat
per
week
four
consecut
week
figur
control
mice
treat
pb
two
week
last
lpselastas
challeng
mice
infect
pfu
influenza
viru
strain
apuerto
viropur
viru
administ
intranas
total
volum
pb
control
mice
receiv
pb
intranas
administr
mice
anesthet
intraperiton
inject
mgkg
ketamin
graeub
mgkg
xylazin
xylasol
graeub
balbc
mice
mgkg
ketamin
mgkg
xylazin
lung
inflat
ml
formalin
embed
paraffin
stain
hematoxylin
eosin
stain
slide
analyz
light
microscopi
pulmonari
emphysema
quantifi
use
imag
j
softwar
measur
mean
linear
intercept
airspac
enlarg
destruct
index
alveolar
wall
destruct
field
view
magnif
per
section
lung
use
quantif
describ
previous
airway
cell
recov
bronchoalveolar
lavag
either
analyz
flow
cytometri
describ
spun
onto
slide
differenti
cell
count
slide
stain
diffquik
dade
count
perform
accord
standard
criteria
total
lung
resist
measur
use
whole
bodi
restrain
plethysmograph
system
flexiv
scireq
mice
anesthet
intramuscular
inject
mgkg
ketamin
graeub
intraperiton
inject
mgkg
pentobarbit
esconarkon
streuli
pharma
subsequ
mice
tracheotom
mechan
ventil
rate
breathsmin
tidal
volum
mlkg
bodyweight
singl
cell
suspens
whole
lung
includ
airway
trachea
obtain
digest
mgml
collagenas
iv
invitrogen
uml
dnasei
roch
neutrophil
monocyt
lung
bronchoalveolar
lavag
fluid
distinguish
stain
biotin
pacif
blue
streptavidin
neutrophil
defin
inflammatori
monocyt
precis
detail
figur
analyz
product
cell
lung
digest
stimul
pma
ionomycin
monensin
h
indic
chemic
purchas
sigmaaldrich
subsequ
cell
subset
distinguish
surfac
stain
fitc
tcr
biotin
pacif
blue
streptavidin
figur
product
character
intracellularli
stain
fixat
bd
lysi
buffer
bd
bioscienc
antibodi
purchas
biolegend
stain
cell
acquir
bd
fac
canto
bd
fac
lsrii
analyz
use
flowjo
softwar
tree
star
neutral
mice
treat
clone
correspond
isotyp
control
antibodi
clone
bioxcel
clone
uniqu
react
isoform
antibodi
administ
intraperiton
one
day
viral
infect
two
day
post
infect
block
signal
mice
receiv
receptor
antagonist
anakinra
kineret
amgen
twice
daili
control
mice
receiv
pb
anakinra
kindli
provid
prof
alexand
centr
hospitali
universitair
vaudoi
lausann
switzerland
mme
ghislain
aubel
centr
hospitali
universitair
vaudoi
lausann
switzerland
total
rna
isol
lung
trachea
tri
reagent
molecular
research
rna
sampl
check
puriti
use
nanodrop
spectrophotomet
thermo
scientif
met
standard
qualiti
criteria
rna
subsequ
transcrib
cdna
iscript
cdna
synthesi
kit
biorad
quantit
realtim
pcr
perform
accord
manufactur
instruct
util
ssoadvanc
sybr
green
supermix
biorad
express
determin
compar
deltathreshold
cycl
method
use
gapdh
compar
follow
primer
use
gapdh
forward
tgt
gaa
cca
cga
gaa
gapdh
revers
tcc
aca
atg
cca
aag
forward
tat
cgc
caa
tga
gct
revers
ctt
gag
tgt
ggc
tat
forward
gaa
ctg
cgc
tgt
caa
revers
ctt
gag
agt
ggc
tat
forward
atc
tag
ctg
aag
ctg
ccc
revers
tag
ggc
act
gtg
gac
gcsf
forward
cac
agc
ttg
tag
gtg
gcsf
revers
tgc
tta
agt
ccc
tgg
forward
cat
cca
gtt
gcc
ttc
revers
ttt
cca
cga
ttt
ccc
aga
forward
ctg
gac
tct
cca
ccg
revers
ggt
cca
gct
ttc
cct
influenza
matrix
protein
forward
ctg
cag
cgt
aga
cgc
influenza
matrix
protein
revers
cct
gtt
gta
tat
gag
gcc
forward
agg
agg
gag
aac
aga
revers
agt
gag
tga
aag
gga
determin
cytokin
level
whole
lung
trachea
collect
store
proteas
inhibitor
solut
roch
use
tissu
homogen
prepar
use
tissuelys
qiagen
protein
determin
use
mous
elisa
kit
readysetgo
ebiosci
follow
manufactur
instruct
measur
sandwich
elisa
use
antimous
biolegend
coat
bound
protein
detect
biotin
label
antibodi
biolegend
subsequ
incub
alkalin
phosphatas
conjug
streptavidin
biolegend
plate
develop
use
substrat
pnitrophenyl
phosphat
sigmaaldrich
od
measur
use
elisa
reader
biotek
statist
signific
differ
assess
use
student
test
two
tail
unpair
pvalu
consid
signific
depict
standard
error
mean
appli
copd
heterogen
diseas
human
core
featur
patholog
reproduc
mice
repetit
exposur
lipopolysaccharid
lp
elastas
lp
bacteri
endotoxin
present
tobacco
smoke
predomin
risk
factor
copd
shown
caus
inflamm
particularli
coadminist
elastas
chronic
emphysemalik
chang
develop
mous
lung
expos
mice
week
consecut
week
mixtur
lp
u
porcin
pancreat
elastas
via
intranas
rout
depict
figur
induc
strong
emphysema
figur
c
sustain
pulmonari
inflamm
figur
balbc
mice
develop
emphysema
score
increas
mean
linear
intercept
destruct
index
figur
lung
histolog
addit
observ
strong
airway
inflamm
mainli
driven
neutrophil
lymphocyt
figur
emphysema
inflamm
remain
baselin
level
least
month
data
shown
thu
respons
induc
repeat
challeng
lpselastas
resembl
patholog
copd
diseas
sever
pronounc
balbc
strain
figur
experi
perform
wild
type
mice
conduct
balbc
mice
studi
viralinduc
exacerb
mice
infect
influenza
viru
week
last
lpselastas
challeng
acut
inflamm
caus
lpselastas
exposur
subsid
figur
peak
viral
replic
reach
day
infect
figur
follow
rapid
declin
viral
titer
figur
complet
viral
clearanc
day
post
infect
data
shown
effici
influenza
infect
strikingli
reduc
mice
pretreat
lpselastas
compar
mice
reveal
significantli
lower
viral
titer
peak
viral
infect
day
day
post
infect
figur
also
reflect
reduc
amount
viabl
viru
lung
day
data
shown
like
due
develop
polyclon
antibodi
respons
observ
upon
lpselastas
treatment
data
shown
thu
respons
influenza
infect
compar
lpselastas
pretreat
naiv
mice
therefor
includ
remaind
studi
invas
measur
pulmonari
resist
lpselastas
pretreat
mice
reveal
viralinduc
acut
exacerb
airway
dysfunct
figur
pulmonari
resist
influenc
varieti
factor
sever
inflamm
like
play
one
key
role
exacerb
line
detect
strong
inflammatori
respons
upon
infect
influenza
viru
associ
augment
absolut
number
cell
infiltr
airway
lung
figur
cell
primarili
neutrophil
figur
figur
inflammatori
monocyt
figur
figur
peak
neutrophil
inflamm
reach
day
post
infect
neutrophil
number
declin
afterward
figur
figur
directli
correl
kinet
viral
replic
figur
line
observ
increas
express
proinflammatori
cytokin
peak
day
post
infect
respect
subsid
day
infect
figur
emphysemat
damag
upon
lpselastas
treatment
also
result
increas
lung
complianc
howev
acut
inflammatori
chang
induc
influenza
infect
impact
increas
lung
complianc
data
shown
acut
pulmonari
dysfunct
neutrophil
inflamm
enhanc
level
proinflammatori
cytokin
observ
exacerb
copd
patient
indic
viralinduc
inflamm
mous
model
line
seen
human
previous
shown
drive
factor
develop
emphysema
inflamm
anim
model
copd
observ
increas
protein
lung
lpselastas
treat
mice
upon
influenza
infect
figur
hypothes
also
promot
innat
immun
respons
influenc
pulmonari
function
exacerb
consequ
expos
defici
wild
type
mice
lpselastas
infect
influenza
viru
describ
strain
show
similar
kinet
neutrophil
inflammatori
monocyt
recruit
upon
viral
exacerb
observ
balbc
mice
figur
figur
note
viral
replic
alter
defici
mice
figur
demonstr
effect
seen
absenc
due
differ
infect
rate
wild
type
mice
exhibit
smaller
chang
pulmonari
resist
respons
viral
infect
figur
comparison
balbc
mice
figur
slight
increas
day
post
infect
figur
nevertheless
pulmonari
resist
mice
lack
significantli
reduc
alreadi
lpselastas
exposur
alon
figur
thu
support
describ
role
develop
chronic
lung
diseas
furthermor
pulmonari
resist
mice
also
complet
unaffect
viral
challeng
figur
detect
impact
inflammatori
monocyt
figur
howev
found
decreas
frequenc
number
neutrophil
noninfect
defici
mice
upon
exposur
lpselastas
figur
figur
similarli
recruit
neutrophil
airway
lung
follow
viral
infect
also
significantli
abrog
absenc
figur
figur
observ
significantli
lower
frequenc
absolut
number
neutrophil
includ
peak
neutrophil
infiltr
viral
replic
day
post
infect
figur
figur
nevertheless
control
viru
unaffect
display
unalt
viral
titer
figur
consid
strong
impact
particularli
upon
neutrophil
sought
address
mechan
mediat
neutrophil
inflamm
express
main
neutrophil
chemoattract
induc
upon
influenza
infect
unaffect
figur
addit
detect
influenc
viral
infect
express
gcsf
figur
given
substanti
redund
neutrophil
chemoattract
thu
next
look
upstream
proinflammatori
cytokin
stimul
neutrophil
inflamm
induc
chemotact
growth
surviv
factor
express
induc
mous
model
upon
influenza
infect
figur
hypothes
drove
observ
inflamm
alter
product
peak
express
upon
influenza
infect
reach
faster
wild
type
mice
day
post
infect
figur
compar
day
balbc
mice
figur
thu
coincid
earlier
respons
pulmonari
resist
observ
strain
figur
protein
level
follow
similar
kinet
mous
strain
figur
b
protein
product
sensit
limit
assay
howev
lack
impair
express
product
figur
figur
fact
increas
express
figur
therefor
focus
proinflammatori
cytokin
shown
elev
copd
patient
whose
induct
partial
depend
found
significantli
reduc
express
level
lung
homogen
absenc
noninfect
well
influenzainfect
lpselastas
expos
mice
figur
product
significantli
reduc
predomin
cellular
sourc
cell
cell
defici
mice
figur
sourc
cell
might
compris
nkt
cell
cell
also
show
reduc
level
absenc
figur
howev
even
wild
type
anim
cell
repres
minor
popul
cell
rel
cell
figur
taken
togeth
data
show
addit
contribut
lung
dysfunct
play
key
role
drive
neutrophil
inflamm
influenzainduc
exacerb
effect
tightli
link
express
assess
whether
inde
mediat
driven
neutrophilia
neutral
influenza
infect
lpselastas
treat
mice
neutral
assay
perform
balbc
mice
exhibit
similar
induct
mice
figur
mice
receiv
either
neutral
antibodi
isotyp
control
antibodi
one
day
two
day
viral
infect
figur
neutral
impact
control
viral
replic
viral
burden
compar
isotyp
control
treat
anim
figur
found
influenzainduc
neutrophil
recruit
airway
lung
inde
entir
attenu
h
infect
absenc
figur
figur
howev
neutrophil
infiltr
lung
airway
later
stage
infect
day
respect
final
reach
frequenc
mice
treat
isotyp
control
figur
figur
thu
indic
requir
initi
later
recruit
neutrophil
henc
driven
neutrophilia
influenza
infect
lpselastas
expos
mice
mediat
earli
phase
infect
becam
independ
data
show
constitut
lack
substanti
impair
neutrophil
infiltr
airway
lung
influenzainduc
exacerb
chronic
lung
inflamm
thu
sought
assess
whether
suffici
block
signal
cours
infect
import
determin
regard
potenti
therapeut
intervent
accordingli
recombin
anakinra
pb
administ
twice
daili
start
two
day
prior
viral
infect
figur
mice
receiv
anakinra
display
impair
earli
control
viral
infect
lead
higher
viral
burden
day
post
infect
although
viral
titer
rapidli
declin
afterward
level
similar
nontreat
mice
day
post
infect
figur
viru
complet
clear
day
post
infect
data
shown
treatment
anakinra
effici
reduc
neutrophil
frequenc
number
airway
day
post
infect
peak
neutrophil
infiltr
viral
replic
figur
figur
observ
effect
anakinra
recruit
inflammatori
monocyt
figur
similarli
detect
signific
chang
lung
function
upon
treatment
anakinra
data
shown
conclus
data
demonstr
influenc
neutrophil
inflamm
influenzainduc
exacerb
chronic
lung
inflamm
mice
throughout
entir
phase
viral
replic
neutrophil
recruit
mediat
first
h
follow
viral
challeng
could
effici
block
earli
phase
infect
antibodi
neutral
peak
inflamm
viral
replic
driven
neutrophilia
independ
could
significantli
reduc
treatment
anakinra
figur
addit
constant
diseas
burden
copd
patient
suffer
episod
acut
symptom
worsen
caus
rapid
declin
respiratori
function
necessit
hospit
even
lead
death
inde
metaanalysi
studi
estim
casefat
rate
follow
hospit
due
exacerb
clear
need
understand
mechan
drive
exacerb
respons
therapi
examin
viralinduc
exacerb
mice
model
figur
mice
develop
strong
inflammatori
respons
character
neutrophil
infiltr
airway
lung
figur
enhanc
express
proinflammatori
cytokin
figur
impair
lung
function
figur
declin
lung
function
neutrophil
accumul
characterist
exacerb
human
elev
level
similarli
measur
sputum
patient
undergo
exacerb
thu
mous
model
reflect
key
patholog
characterist
copd
exacerb
human
given
signific
differ
suscept
pb
treat
lpselastas
treat
mice
figur
data
shown
might
due
develop
polyclon
bcell
respons
upon
lpselastas
administr
believ
conclus
drawn
comparison
stabl
diseas
versu
episod
exacerb
notabl
also
support
find
cigarett
smoke
cs
model
pulmonari
inflamm
cs
expos
mice
show
consider
alter
respons
influenza
infect
well
acceler
clearanc
haemophilu
influenza
comparison
control
mice
studi
specif
focus
role
proinflammatori
cytokin
signal
shown
essenti
recruit
neutrophil
mous
model
mimick
patholog
stabl
copd
exposur
cigarett
smoke
elastas
alon
build
upon
studi
found
influenzainduc
exacerb
pulmonari
accumul
neutrophil
also
driven
figur
figur
data
line
result
studi
botelho
et
al
investig
mous
model
acut
cigarett
smoke
exposur
found
receptor
defici
led
reduct
neutrophil
follow
infect
influenza
effect
independ
one
could
therefor
specul
may
play
critic
role
neutrophil
recruit
model
well
cytokin
play
central
role
amplifi
inflammatori
cascad
induc
varieti
chemokin
cytokin
also
report
contribut
develop
emphysema
immunopatholog
follow
influenza
infect
line
found
mediat
earli
inflamm
model
influenzainduc
exacerb
chronic
lung
diseas
figur
data
show
driven
neutrophil
recruit
first
h
infect
mediat
becam
independ
later
time
point
exacerb
found
absenc
express
complet
abrog
upon
lpselastas
exposur
well
exacerb
figur
thu
demonstr
requir
induct
express
induc
lpselastas
exposur
alon
level
maintain
throughout
viralinduc
exacerb
figur
g
howev
level
increas
later
phase
infect
figur
express
surprisingli
remain
unalt
even
decreas
peak
viral
replic
figur
nevertheless
could
block
recruit
neutrophil
earli
time
point
follow
influenza
infect
neutral
figur
peak
viral
replic
thu
sever
state
inflamm
neutral
could
prevent
neutrophil
influx
might
due
induct
cytokin
progress
infect
could
overcom
effect
therefor
treatment
seem
favor
earli
phase
exacerb
block
might
advantag
ongo
infect
whether
find
translat
clinic
set
remain
investig
keep
mind
neutrophil
recruit
elev
vast
major
case
copd
exacerb
regardless
etiolog
furthermor
increas
neutrophil
sputum
correl
exacerb
sever
attenu
neutrophilia
could
benefici
patient
undergo
viralinduc
exacerb
current
treatment
reli
mainli
corticosteroid
bronchodil
shown
reduc
frequenc
exacerb
posit
effect
ongo
episod
exacerb
inde
reduct
inflammatori
respons
includ
neutrophil
influx
mice
cytokin
express
human
could
achiev
treatment
steroid
copd
exacerb
contrast
corticosteroid
shown
actual
support
neutrophil
surviv
moreov
treatment
corticosteroid
effici
reduc
level
stabl
copd
affect
amount
protein
exhal
breath
condens
exacerb
block
either
figur
figur
figur
effici
reduc
neutrophil
inflamm
viral
exacerb
two
molecul
could
consid
potenti
target
therapeut
intervent
given
redund
two
inflammatori
pathway
combin
therapi
may
prove
benefici
improv
lung
function
within
context
target
clinic
one
keep
mind
alter
proinflammatori
immun
respons
harbor
risk
interf
control
acut
infect
suscept
opportunist
infect
shorten
durat
intervent
therebi
reduc
risk
prolong
secondari
infect
treat
mice
directli
viral
infect
figur
figur
suffici
abrog
neutrophil
recruit
indic
time
point
furthermor
neutral
promot
elev
viral
replic
figur
treatment
therebi
block
led
increas
viral
titer
initi
phase
infect
figur
wherea
absenc
alon
affect
viral
replic
figur
therefor
like
model
initi
control
viru
might
mediat
rather
line
data
botelho
et
al
found
similarli
elev
viral
titer
upon
neutral
complet
absenc
data
thu
suggest
target
specif
receptor
would
favor
therapeut
applic
howev
treatment
anakinra
interfer
final
viral
clearanc
still
could
consid
therapeut
approach
addit
advantag
alreadi
use
clinic
indic
taken
togeth
data
demonstr
block
signal
influenzainduc
exacerb
diminish
neutrophil
infiltr
distinct
phase
infect
whether
mechan
appli
also
respiratori
viral
infect
remain
elucid
howev
plausibl
given
common
earli
inflammatori
pathway
induc
respiratori
viral
infect
overal
blockad
could
valuabl
therapeut
option
futur
treatment
viral
induc
exacerb
chronic
lung
inflamm
